Debbie Rigby rounds up the latest in research news
A systematic review and meta-analysis of nearly 150,00 people has concluded that omega-3 FA are associated with reducing cardiovascular mortality, non-fatal myocardial infarction, coronary heart disease events, major adverse cardiovascular events (MACE) and revascularization. The cardiovascular risk reduction was more prominent with EPA monotherapy than with EPA+DHA. Omega-3 FA increased incident AF and EPA monotherapy was associated with a higher risk of total bleeding than controls.
EClinicalMedicine 000 (2021) 100997
In a large UK trial, amlodipine-based blood pressure regimen reduced the long-term incidence of stroke compared with an atenolol-based regimen but had no measurable effect on dementia. Atorvastatin had no effect on either stroke or dementia. Higher BP variability was associated with a higher incidence of later dementia and stroke.
Post-hoc analysis of data from the ASPREE trial shows no association between statin use and incident dementia, mild cognitive impairment, or declines in individual cognition in people aged 65 years and older. No differences were found in any outcomes between hydrophilic and lipophilic statin users.
J Am Coll Cardiol 2021;77(25):3145-56.
A systematic review and meta-analysis of 49 randomised controlled trials has found little evidence about the clinical efficacy and safety of muscle relaxants in non-specific low back pain. There was weak evidence that non-benzodiazepine antispasmodics such as orphenadrine might provide small but not clinically important reductions in pain intensity at or before two weeks and might increase the risk of an adverse event in acute low back pain.